The impactful role MSLs play in maximizing new innovation for patients Launching innovative therapies in the competitive biopharma space is increasingly challenging. Launch Excellence research by IQVIA highlights the three key challenges to achieving launch success are healthcare system capacity gaps, achieving timely and compelling evidence and HCP engagement1. Each of … [Read more...]
Optimizing Expert Identification and Engagement to Improve Rare Disease Outcomes
Orphan drug approvals by the U.S. Food & Drug Administration (FDA) have increased steadily since 2010. For four of the past five years, they have comprised more than half of all drugs approved per year,. Yet, despite this, only 10 percent of the 7,000 recognized rare diseases have FDA-approved therapies. Consequently, there is relatively little research regarding some 90 … [Read more...]
The Importance of Using the Right Impact Metrics in KOL Management
The scientific landscape and the ways in which we share and view evidence continue to change at a very rapid pace. Key opinion leaders (KOLs) are interacting with and educating colleagues, patients, and the general public in new ways, and the methodologies that we use to evaluate our engagement with them have also evolved. As MSL teams -- and the levels of their visibility -- … [Read more...]